Mesenchymal transition and pdgfra amplification/mutation are key distinct oncogenic events in pediatric diffuse intrinsic pontine gliomas

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Puget, Stephanie ^a,b   Philippe, Cathy ^b   Bax, Dorine A ^c   Job, Bastien ^d   Varlet, Pascale ^e   Junier, Marie Pierre ^e   Andreiuolo, Felipe ^b   Carvalho, Dina ^c,f,g   Reis, Ricardo ^f   Guerrini Rousseau, Lea ^b   Roujeau, Thomas ^a   Dessen, Philippe ^d   Richon, Catherine ^b   Lazar, Vladimir ^b   Teuff, Gwenael ^b   Sainte Rose, Christian ^a   Geoerger, Birgit ^b   Vassal, Gilles ^b   Jones, Chris ^c   Grill, Jacques ^b  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e INSERM   (France)

^f UNIVERSITY OF MINHO   (Portugal)

^g UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; RNA; SNAIL FAMILY TRANSCRIPTION FACTORS; TRANSCRIPTION FACTOR;

ARTICLE; BRAIN TUMOR; CANCER CLASSIFICATION; CANCER MORTALITY; CANCER STEM CELL; CARCINOGENESIS; CELL TRANSFORMATION; CHILD; CHROMOSOME ABERRATION; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DIFFUSE INTRINSIC PONTINE GLIOMA; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MESENCHYMAL TRANSITION; MISSENSE MUTATION; MOLECULARLY TARGETED THERAPY; PONTINE GLIOMA; PROGNOSIS; SIGNAL TRANSDUCTION; STEREOTACTIC BIOPSY; TUMOR DIFFERENTIATION; BRAIN STEM TUMOR; EPITHELIAL MESENCHYMAL TRANSITION; GENETICS; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; METABOLISM; METHODOLOGY; MUTATION; PATHOLOGY;

BRAIN STEM NEOPLASMS; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; MUTATION; PONTINE GLIOMA; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 84857527038     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030313     Document Type: Article

References (79)

1. Qaddoumi I, Sultan I, Gajjar A, (2009) Outcome and prognostic features in pediatric gliomas: a review of 6212 cases from the Surveillance, Epidemiology, and End Results database. Cancer 115: 5761-5770.
2. Hargrave D, Bartels U, Bouffet E, (2006) Diffuse brainstem glioma in children: critical review of clinical trials. The lancet oncology 7: 241-248.
3. Donaldson SS, Laningham F, Fisher PG, (2006) Advances toward an understanding of brainstem gliomas. J Clin Oncol 24: 1266-1272.
4. Herrington B, Kieran MW, (2009) Small molecule inhibitors in children with malignant gliomas. Pediatr Blood Cancer 53: 312-317.
5. Jalali R, Raut N, Arora B, Gupta T, Dutta D, et al. (2010) Prospective evaluation of radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma. Int J Radiat Oncol Biol Phys 77: 113-118.
6. Bax DA, Mackay A, Little SE, Carvalho D, Viana-Pereira M, et al. (2010) A distinct spectrum of copy number aberrations in pediatric high-grade gliomas. Clin Cancer Res 16: 3368-3377.
7. Qu HQ, Jacob K, Fatet S, Ge B, Barnett D, et al. (2010) Genome-wide profiling using single-nucleotide polymorphism arrays identifies novel chromosomal imbalances in pediatric glioblastomas. Neuro-oncology 12: 153-163.
8. Paugh BS, Qu C, Jones C, Liu Z, Adamowicz-Brice M, et al. (2010) Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol 28: 3061-3068.
9. Barrow J, Adamowicz-Brice M, Cartmill M, MacArthur D, Lowe J, et al. (2011) Homozygous loss of ADAM3A revealed by genome-wide analysis of pediatric high-grade glioma and diffuse intrinsic pontine gliomas. Neuro Oncol 13: 212-222.
10. Zarghooni M, Bartels U, Lee E, Buczkowicz P, Morrison A, et al. (2010) Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets. J Clin Oncol 28: 1337-1344.
11. Albright AL, Packer RJ, Zimmerman R, Rorke LB, Boyett J, et al. (1993) Magnetic resonance scans should replace biopsies for the diagnosis of diffuse brain stem gliomas: a report from the Children's Cancer Group. Neurosurgery 33: 1026-1029 discussion 1029-1030.
12. Hargrave D, (2008) Pontine glioma. To biopsy or not to biopsy: that is the question. Brit J Neurosurg 22: 624.
13. Schumacher M, Schulte-Monting J, Stoeter P, Warmuth-Metz M, Solymosi L, (2007) Magnetic resonance imaging compared with biopsy in the diagnosis of brainstem diseases of childhood: a multicenter review. J Neurosurg 106: 111-119.
14. Pincus DW, Richter EO, Yachnis AT, Bennett J, Bhatti MT, et al. (2006) Brainstem stereotactic biopsy sampling in children. J Neurosurg 104: 108-114.
15. Louis DN, Rubio MP, Correa KM, Gusella JF, von Deimling A, (1993) Molecular genetics of pediatric brain stem gliomas. Application of PCR techniques to small and archival brain tumor specimens. J Neuropathol Exp Neurol 52: 507-515.
16. Gilbertson RJ, Hill DA, Hernan R, Kocak M, Geyer R, et al. (2003) ERBB1 is amplified and overexpressed in high-grade diffusely infiltrative pediatric brain stem glioma. Clin Cancer Res 9: 3620-3624.
17. Okada H, Low KL, Kohanbash G, McDonald HA, Hamilton RL, et al. (2008) Expression of glioma-associated antigens in pediatric brain stem and non-brain stem gliomas. J Neuro-oncol 88: 245-250.
18. Broniscer A, Baker JN, Baker SJ, Chi SN, Geyer JR, et al. (2010) Prospective collection of tissue samples at autopsy in children with diffuse intrinsic pontine glioma. Cancer 116: 4632-4637.
19. Roujeau T, Machado G, Garnett MR, Miquel C, Puget S, et al. (2007) Stereotactic biopsy of diffuse pontine lesions in children. J Neurosurg 107: 1-4.
20. Geoerger B, Morland B, Ndiaye A, Doz F, Kalifa G, et al. (2009) Target-driven exploratory study of imatinib mesylate in children with solid malignancies by the Innovative Therapies for Children with Cancer (ITCC) European Consortium. Eur J Cancer 45: 2342-2351.
21. Geoerger B, Hargrave D, Thomas F, Ndiaye A, Frappaz D, et al. (2010) Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. Neuro-oncology 13: 109-118.
22. Guillemot V, Philippe C, Tenenhaus A, Rollin J, Gidrol X, et al. (2008) Grouping levels of Exposure with same Observable Effects before Class Prediction in Toxicogenomics. Paper presented at: International Conference on Bioinformatics and Biomedical Technologies (BIOTECHNO'08) Digital Library, ISBN: 978-0-7695-3191-5, pp.164-169. Bucharest, Rumania, June 29th-July 5th.
23. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad of Sci USA 102: 15545-15550.
24. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, et al. (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17: 98-110.
25. Carro MS, Lim WK, Alvarez MJ, Bollo RJ, Zhao X, et al. (2010) The transcriptional network for mesenchymal transformation of brain tumours. Nature 463: 318-325.
26. Lin K, Baritaki S, Militello L, Malaponte G, Bevelacqua Y, et al. (2010) The Role of B-RAF Mutations in Melanoma and the Induction of EMT via Dysregulation of the NF-kappaB/Snail/RKIP/PTEN Circuit. Genes Cancer 1: 409-420.
27. Schiffman JD, Hodgson JG, VandenBerg SR, Flaherty P, Polley MY, et al. (2010) Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res 70: 512-519.
28. Thirant C, Bessette B, Varlet P, Puget S, Cadusseau J, et al. (2011) Clinical relevance of tumor cells with stem-like properties in pediatric brain tumors. PLoS ONE 6: e16375.
29. Takada N, Kucenas S, Appel B, (2010) Sox10 is necessary for oligodendrocyte survival following axon wrapping. Glia 58: 996-1006.
30. Pozniak CD, Langseth AJ, Dijkgraaf GJ, Choe Y, Werb Z, et al. (2010) Sox10 directs neural stem cells toward the oligodendrocyte lineage by decreasing Suppressor of Fused expression. Proc Natl Acad Sci U S A 107: 21795-800.
31. Negri T, Bozzi F, Conca E, Brich S, Gronchi A, et al. (2009) Oncogenic and ligand-dependent activation of KIT/PDGFRA in surgical samples of imatinib-treated gastrointestinal stromal tumours (GISTs). J Pathol 217: 103-112.
32. Lei L, Sonabend AM, Guarnieri P, Soderquist C, Ludwig T, et al. (2011) Glioblastoma models reveal the connection between adult glial progenitors and the proneural phenotype. PLoS ONE 6 (5): e20041.
33. Cahoy JD, Emery B, Kaushal A, Foo LC, Zamanian JL, et al. (2008) A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function. J Neurosci 28 (1): 264-278.
34. Gilbertson RJ, Gutmann DH, (2007) Tumorigenesis in the brain: location, location, location. Cancer Res 67: 5579-5582.
35. Taylor MD, Poppleton H, Fuller C, Su X, Liu Y, et al. (2005) Radial glia cells are candidate stem cells of ependymoma. Cancer Cell 8: 323-335.
36. Modena P, Lualdi E, Facchinetti F, Veltman J, Reid JF, et al. (2006) Identification of tumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics. J Clin Oncol 24: 5223-5233.
37. Palm T, Figarella-Branger D, Chapon F, Lacroix C, Gray F, et al. (2009) Expression profiling of ependymomas unravels localization and tumor grade-specific tumorigenesis. Cancer 115: 3955-3968.
38. Andreiuolo F, Puget S, Peyre M, Dantas-Barbosa C, Boddaert N, et al. (2010) Neuronal differentiation distinguishes supratentorial and infratentorial childhood ependymomas. Neuro-oncology 12: 1126-1134.
39. Sharma MK, Mansur DB, Reifenberger G, Perry A, Leonard JR, et al. (2007) Distinct genetic signatures among pilocytic astrocytomas relate to their brain region origin. Cancer Res 67: 890-900.
40. Lee Y, Kawagoe R, Sasai K, Li Y, Russell HR, et al. (2007) Loss of suppressor-of-fused function promotes tumorigenesis. Oncogene 26: 6442-6447.
41. Monje M, Mitra SS, Freret ME, Raveh TB, Kim J, et al. (2011) Hedgehog-responsive candidate cell of origin for diffuse intrinsic pontine glioma. Proc Natl Acad Sci 108: 4453-4458.
42. Puget S, Crimmins DW, Garnett MR, Grill J, Oliveira R, et al. (2007) Thalamic tumors in children: a reappraisal. J Neurosurg 106: 354-362.
43. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, et al. (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9: 157-173.
44. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, et al. (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756-760.
45. Ducray F, de Reynies A, Chinot O, Idbaih A, Figarella-Branger D, et al. (2010) An ANOCEF genomic and transcriptomic microarray study of the response to radiotherapy or to alkylating first-line chemotherapy in glioblastoma patients. Molecular Can 9: 234.
46. Kessler J, Hahnel A, Wichmann H, Rot S, Kappler M, et al. (2010) HIF-1alpha inhibition by siRNA or chetomin in human malignant glioma cells: effects on hypoxic radioresistance and monitoring via CA9 expression. BMC Cancer 10: 605.
47. Cao F, Hata R, Zhu P, Nakashiro K, Sakanaka M, et al. (2010) Conditional deletion of Stat3 promotes neurogenesis and inhibits astrogliogenesis in neural stem cells. Biochem Biophys Res Commun 394: 843-847.
48. Garcia JL, Perez-Caro M, Gomez-Moreta JA, Gonzalez F, Ortiz J, et al. (2010) Molecular analysis of ex-vivo CD133+ GBM cells revealed a common invasive and angiogenic profile but different proliferative signatures among high grade gliomas. BMC Cancer 10: 454.
49. Liu Q, Nguyen DH, Dong Q, Shitaku P, Chung K, et al. (2009) Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors. J Neuro-oncol 94: 1-19.
50. Kurrey NK, Jalgaonkar SP, Joglekar AV, Ghanate AD, Chaskar PD, et al. (2009) Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem cells (Dayton, Ohio) 27: 2059-2068.
51. Lucas JT Jr, Salimath BP, Slomiany MG, Rosenzweig SA, (2010) Regulation of invasive behavior by vascular endothelial growth factor is HEF1-dependent. Oncogene 29: 4449-4459.
52. Wang Y, Ngo VN, Marani M, Yang Y, Wright G, et al. (2010) Critical role for transcriptional repressor Snail2 in transformation by oncogenic RAS in colorectal carcinoma cells. Oncogene 29: 4658-4670.
53. Faury D, Nantel A, Dunn SE, Guiot MC, Haque T, et al. (2007) Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. J Clin Oncol 25: 1196-1208.
54. Cooper LA, Gutman DA, Long Q, Johnson BA, Cholleti SR, et al. (2010) The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas. PloS ONE 5: e12548.
55. Ducray F, Idbaih A, de Reynies A, Bieche I, Thillet J, et al. (2008) Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile. Molecular Can 7: 41.
56. Freije WA, Castro-Vargas FE, Fang Z, Horvath S, Cloughesy T, et al. (2004) Gene expression profiling of gliomas strongly predicts survival. Cancer Res 64: 6503-6510.
57. Rowitch DH, Kriegstein AR, (2010) Developmental genetics of vertebrate glial-cell specification. Nature 468: 214-222.
58. Mehta S, Huillard E, Kesari S, Maire CL, Golebiowski D, et al. (2011) The central nervous system-restricted transcription factor Olig2 opposes p53 responses to genotoxic damage in neural progenitors and malignant glioma. Cancer Cell 19: 359-371.
59. De Carli E, Wang X, Puget S, (2009) IDH1 and IDH2 mutations in gliomas. New Engl J Med 360: 2248.
60. Pollack IF, Hamilton RL, Sobol RW, Nikiforova MN, Lyons-Weiler MA, et al. (2011) IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children's Oncology Group. Childs Nerv Syst 27: 87-94.
61. Ferletta M, Uhrbom L, Olofsson T, Ponten F, Westermark B, (2007) Sox10 has a broad expression pattern in gliomas and enhances platelet-derived growth factor-B-induced gliomagenesis. Mol Cancer Res 5: 891-897.
62. Lindberg N, Kastemar M, Olofsson T, Smits A, Uhrbom L, (2009) Oligodendrocyte progenitor cells can act as cell of origin for experimental glioma. Oncogene 28: 2266-2275.
63. Appolloni I, Calzolari F, Tutucci E, Caviglia S, Terrile M, et al. (2009) PDGF-B induces a homogeneous class of oligodendrogliomas from embryonic neural progenitors. Int J Cancer 124: 2251-2259.
64. Masui K, Suzuki SO, Torisu R, Goldman JE, Canoll P, et al. (2010) Glial progenitors in the brainstem give rise to malignant gliomas by platelet-derived growth factor stimulation. Glia 58: 1050-1065.
65. Becher OJ, Hambardzumyan D, Walker TR, Helmy K, Nazarian J, et al. (2010) Preclinical evaluation of radiation and perifosine in a genetically and histologically accurate model of brainstem glioma. Cancer Res 70: 2548-2557.
66. Lee JC, Vivanco I, Beroukhim R, Huang JH, Feng WL, et al. (2006) Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS medicine 3: e485.
67. Ozawa T, Brennan CW, Wang L, Squatrito M, Sasayama T, et al. (2010) PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas. Genes Dev 24: 2205-2218.
68. Pollack IF, Jakacki RI, Blaney SM, Hancock ML, Kieran MW, et al. (2007) Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. Neuro-oncology 9: 145-160.
69. Holdhoff M, Supko JG, Gallia GL, Hann CL, Bonekamp D, et al. (2010) Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme. J Neuro-oncol 97: 241-245.
70. Wen PY, Yung WKA, Lamborn KR, Dahia PL, Wang Y, et al. (2006) Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res 12: 4899-4907.
71. Paulsson J, Lindh MB, Jarvius M, Puputti M, Nister M, et al. (2011) Prognostic but not predictive role of platelet-derived growth factor receptors in patients with recurrent glioblastoma. Int J Cancer 128: 1981-1988.
72. Holdhoff M, Kreuzer KA, Appelt C, Scholz R, Na IK, et al. (2005) Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor. Blood Cells Mol Dis 34: 181-185.
73. Russell JS, Brady K, Burgan WE, Cerra MA, Oswald KA, et al. (2003) Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity. Cancer Res 63: 7377-7383.
74. Kast RE, Focosi D, (2010) Three paths to better tyrosine kinase inhibition behind the blood-brain barrier in treating chronic myelogenous leukemia and glioblastoma with imatinib. Translat Oncol 3: 13-15.
75. Lagas JS, van Waterschoot RAB, van Tilburg VACJ, Hillebrand MJ, Lankheet N, et al. (2009) Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment. Clin Cancer Res 15: 2344-2351.
76. Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, et al. (2007) Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science (New York, NY) 318: 287-290.
77. Bax DA, Gaspar N, Little SE, Marshall L, Perryman L, et al. (2009) EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines. Clin Cancer Res 15: 5753-5761.
78. Diskin SJ, Eck T, Greshock J, Mosse YP, Naylor T, et al. (2006) STAC: A method for testing the significance of DNA copy number aberrations across multiple array-CGH experiments. Genome Res 16: 1149-1158 (2006).
79. Salari K, Tibshirani R, Pollack JR, (2010) DR-Integrator: a new analytic tool for integrating DNA copy number and gene expression data. Bioinformatics (Oxford, England) 26: 414-416.